Menu
← Oncology Approval Tracker
FDA DECISION ·
Kyprolis + Sarclisa + dexamethasone
carfilzomib plus isatuximab-irfc and dexamethasone · Onyx Therapeutics / Amgen
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
The Isa-Kd regimen for adults with relapsed or refractory multiple myeloma following one to three previous therapy lines.
LAMPGEN ANALYSIS
Why it matters
The decision adds the isatuximab-based regimen to the carfilzomib label.
What research teams should watch
Document the prior-line count and coordinate administration and monitoring for the individual regimen components.
PRIMARY RECORDS